Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Brain Cancer

Brain Cancer

26

Pipeline Programs↗

29

Active Trials↗

18

Companies Involved↗

Brain Cancer is an emerging landscape with 26 programs across 18 companies. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

32/100

Mech. Concentration

13/100

Completion Rate

88/100

Attrition Rate

5/100

Pipeline

Programs by Phase

Preclinical13

Motexafin Gadolinium

Pharmacyclics LLC.

Ergocalciferol

Jazz Pharmaceuticals

Gadolinium

OHSU Knight Cancer Institute

Sulfasalazine

Pfizer

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 14

Nivolumab-Irdye800

Eben Rosenthal

NLG802

Luke, Jason, MD

Ipilimumab

Bristol-Myers Squibb

Hyperpolarized 13-C-Pyruvate

M.D. Anderson Cancer Center

Phase 28

Valganciclovir

Engelhard Arzneimittel GmbH & Co.KG

Aguix Gadolinium-Based Nanoparticles

Brigham and Women's Hospital

Trastuzumab

Roche

Pembrolizumab

Merck & Co.

Interleukin 2

Essen Biotech

Phase 31

Nivolumab

Bristol-Myers Squibb

Approved

No programs

Analysis

Modality Breakdown

63%

Small molecule

15 of 24 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 24 classified programs, each share of the total. Modality classified for 92% of 26 pipeline programs.

Analysis

Trial Status

57

clinical trials

Completed23 · 40%

Recruiting17 · 30%

Active, not recruiting8 · 14%

Not yet recruiting4 · 7%

Unknown status2 · 4%

Terminated2 · 4%

Other1 · 2%

Clinical Trials

Trial Activity

57 trials

Pilot Study of the Living Well With Brain Cancer Intervention

Recruiting·UUniversity of Colorado, Denver·Preclinical·NCT07628647·64 enrolled

ET-NEURO: A Pilot Trial of the Exercise Together Program in Primary Brain Tumor Patient-Caregiver Dyads Incorporating Glymphatic MRI

Recruiting·OOHSU Knight Cancer Institute·Preclinical·NCT07278440·36 enrolled

Phase I Study of Cellular Immunotherapy Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Children With Recurrent/Refractory Malignant Brain Tumors

Recruiting·CCity of Hope Medical Center·Phase 1·NCT04510051·18 enrolled

Using Advanced MR Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans: A Pilot Study, and to Examine Metabolite Changes in Gliomas and Other Solid Tumors

Recruiting·MMemorial Sloan Kettering Cancer Center·Preclinical·NCT00870129·135 enrolled

Surgical Resection of Latent Brain Tumors Prior to Recurrence

Recruiting·MMayo Clinic·Preclinical·NCT04810871·40 enrolled

A Pilot Study Assessing the Safety of an Active Surveillance Approach to Local Therapy in Patients With Brain Metastases Undergoing CNS-Penetrating Systemic Therapy

Recruiting·UUniversity of California, Irvine·N/A·NCT07827001·12 enrolled

A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation Alone

Recruiting·BBrigham and Women's Hospital·Phase 2·NCT04899908·134 enrolled

Initial Safety Lead-in Followed by a Phase II Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection (The Breast CMV Study)

Recruiting·TThe Methodist Hospital Research Institute·Phase 2·NCT07383649·28 enrolled

Ommaya Reservoir Placement at the Time of Biopsy for Longitudinal Biomarker Collection

Recruiting·MMayo Clinic·Preclinical·NCT06322602·30 enrolled

Hyperpolarized Pyruvate Imaging of Glioma: Imaging-Pathological Correlation

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT03830151·13 enrolled

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

Recruiting·—·Phase 1·NCT07210632·38 enrolled

Phase I/II, Open-Label Study Evaluating the Efficacy and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Neoplasms During Neurosurgical Procedures

Recruiting·SStanford University·Preclinical·NCT03510208·46 enrolled

A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.

Recruiting·UUniversity College, London·Phase 1·NCT07134842·16 enrolled

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06058988·30 enrolled

Study of How Safe and Effective Tarlatamab is in Brain Cancers

Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT06776250·44 enrolled

Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)